Knowledge Graphs and Explainable AI for Drug Repurposing on Rare Diseases
Pablo Perdomo-QuinteiroiD, Katherine WolstencroftiD, Marco RoosiD, Núria Queralt-RosiñachiD
Abstract
Artificial Intelligence (AI)-based drug repurposing is an emerging strategy to identify drug candidates to treat rare diseases. However, cutting-edge algorithms based on Deep Learning (DL) typically dont provide a human understandable explanation supporting their predictions. This is a problem because it hampers the biologists ability to decide which predictions are the most plausible drug candidates to test in costly lab experiments. In this study, we propose rd-explainer a novel AI drug repurposing method for rare diseases which obtains possible drug candidates together with human understandable explanations. The method is based on Graph Neural Network (GNN) technology and explanations were generated as semantic graphs using state-of-the-art eXplainable AI (XAI). The model learns features from current background knowledge on the target rare disease structured as a Knowledge Graph (KG), which integrates curated facts and their evidence on different biomedical entities such as symptoms, drugs, genes and ortholog genes. Our experiments demonstrate that our method has excellent performance that is superior to state-of-the-art models. We investigated the application of XAI on drug repurposing for rare diseases and we prove our method is capable of discovering plausible drug candidates based on testable explanations. The data and code are publicly available at https://github.com/PPerdomoQ/rare-disease-explainer. HighlightsO_LIWe demonstrated the use of graph-based explainable AI for drug repurposing on rare diseases to accelerate sound discovery of new therapies for this underrepresented group. C_LIO_LIWe developed rd-explainer for rare disease specific drug research for faster translation. It predicts drugs to treat symptoms/phenotypes, it is highly performant and novel candidates are plausible according to evidence in the scientific literature and clinical trials. Key is that it learns a GNN model that is trained on a knowledge graph built specifically for a rare disease. We provide rd-explainer code freely available for the community. C_LIO_LIrd-explainer is researcher-centric interpretable ML for hypothesis generation and lab-in-the-loop drug research. Explanations of predictions are semantic graphs in line with human reasoning. C_LIO_LIWe detected an effect of knowledge graph topology on explainability. This highlights the importance of knowledge representation for the drug repurposing task. C_LI
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 6
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Deep Learning-Based Drug Repurposing Using Knowledge Graph Embeddings and GraphRAG
Herbert George, Gowtham Baratam, DS Dhyaneesh·bioRxiv·Dec 10, 2025
- COMIC: Explainable Drug Repurposing via Contrastive Masking for Interpretable Connections
Naafey Aamer, Muhammad Nabeel Asim, A. Dengel·BMC BioinformaticsPeer-reviewed·Jan 9, 2026
- A Literature-Based Knowledge Graph Embedding Method for Identifying Drug Repurposing Opportunities in Rare Diseases
Daniel N. Sosa, Alexander Derry, … Russ Biagio Altman·Pacific Symposium on Biocomputing (PSB)Peer-reviewed·Nov 27, 2019
- Riemann-GNN: Causal Reasoning on Hyperbolic Riemannian Manifolds for Interpretable Drug-Disease Prediction
Jingjing Yang, Puyu Han, … Jie Tao·bioRxiv·May 16, 2025
- KGML-xDTD: A Knowledge Graph-based Machine Learning Framework for Drug Treatment Prediction and Mechanism Description
Chunyu Ma, Zhihan Zhou, … David Koslicki·GigaSciencePeer-reviewed·Dec 28, 2022
- BioScientist Agent: Designing LLM-Biomedical Agents with KG-Augmented RL Reasoning Modules for Drug Repurposing and Mechanistic of Action Elucidation
Fan Zhang, Yalong Zhao, … Lipeng Lai·bioRxiv·Aug 8, 2025